Ülviye Oflas· @ulvyeoflas · X·· 1 天前评分70
正文 · 原文
📢 #ESMO26 | Phase III #postMONARCH
🔹 Median OS: 32.1 vs 24.6 months (+7.5 months)
🔹 HR 0.80 (95% CI 0.60–1.06)
🔹 OS numerically favored abemaciclib + fulvestrant, but did not reach statistical significance.
📌 Encouraging OS trend following CDK4/6i progression.
#BreastCancer #HRpositive @KalinskyKevin
22 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Ülviye Oflas · x.com